We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies
In our technology platforms, we use a variety of different payloads to research, manufacture and clinically develop highly effective ADCs for the treatment of a variety of malignant hematological and solid tumors. ADCs combine the high affinity and specificity of antibodies with the potency of small toxic molecules to fight cancer.
With our unique expertise in the active ingredient Amanitin from the green death cap mushroom, we have developed a patented and proprietary ATAC technology. The toxin's unique mode of action offers the opportunity to break through drug resistance and eliminate even quiescent tumor cells, which could lead to significant advances in cancer therapy – even for patients who no longer respond to any other treatment.
PR: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma | 27 May 2025 | Open |
PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board | 15 May 2025 | Open |
PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 | 14 May 2025 | Open |
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 | 24 April 2025 | Open |
Title | Date | |
---|---|---|
Telix: FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review | 26 February 2025 | Read more |
Telix: Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging | 30 December 2024 | Read more |
Telix: First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients | 28 November 2024 | Read more |
Telix: First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery | 3 October 2024 | Read more |